The Federalist: In the Genital Mutilation Market, Business is Booming

According to market research, predictions estimate that the "gender-affirming care" industry will grow to $5 billion before the end of the decade.

Read the full article by Jay Richards here.

"I spend my days studying a new line of business called "gender-affirming care." That's a euphemism for the current craze of treating teenagers who struggle with gender dysphoria." Jay Richards writes in the Federalist.

Richards claims doctors who participate in this practice are using drugs and performing surgeries that cut into these patient's young bodies to "affirm" their self-diagnosed internal sense of gender. "Don't ask for a better explanation. There isn't one," Richards said.

Referencing a new report just released by Grand View Research, Richards describes growing jaded after reading about "top surgeries," "bottom surgeries," and sterilizing teenagers.

According to the report, just in the United States, the market for such surgeries is estimated to grow to $5 billion by the end of the decade. In 2021, the market was valued at USD 1.9 billion but is expected to have a compound annual growth rate of 11.23% from 2022 to 2030.

"Business is booming because of “rising incidences of gender dysphoria and the increasing number of people opting for gender confirmation surgeries," Richards wrote.

The report fails to account for potential revenue stemming from complications that arise from these procedures.

"Simply cutting out a uterus, or cutting off a penis, may only generate revenue once. These tend to be one-and-done operations. But constructing a simulacrum of a penis and attaching it to a woman involves the rerouting of blood vessels, skin, urethra, and nerves. This is far from simple. The initial surgery can take many hours. The follow-up for complications, infections, and maintenance can stretch out for years," Richards writes.

Here is testimony from one patient, Scott Newgent:

During my own transition, I had seven surgeries. I also had a massive pulmonary embolism, a helicopter life-flight ride, an emergency ambulance ride, a stress-induced heart attack, sepsis, a 17-month recurring infection due to using the wrong skin during a (failed) phalloplasty, 16 rounds of antibiotics, three weeks of daily IV antibiotics, the loss of all my hair, (only partially successful) arm reconstructive surgery, permanent lung and heart damage, a cut bladder, insomnia-induced hallucinations—oh and frequent loss of consciousness due to pain from the hair on the inside of my urethra. All this led to a form of PTSD that made me a prisoner in my apartment for a year. Between me and my insurance company, medical expenses exceeded $900,000.

It seems that Grand View Research overlooked testimonies such as this. Richards also points out how much money is to be made for each transgender patient.

"And this is to say nothing of the life-long need for cross-sex hormones. You see, even after a woman has had her breasts, uterus, and fallopian tubes removed, and the skin, nerves, and muscle from her forearm stripped and refashioned in a neo-penis, every cell of her body is going to go right on thinking it’s female. That’s hard on the patient, but if she lives to be 70 or 80, can you imagine the revenue from exogenous testosterone alone? How did this financial research firm miss this part of the story?" Richards asks.

Read the full article here.

Jay W. Richards, Ph.D., is author of many books including the New York Times bestsellers Infiltrated (2013) and Indivisible (2012), and the William E. Simon senior research fellow in Heritage’s DeVos Center for Religion and Civil Society.